查看文章

Discussion

Although the Food and Drug Administration approved tumor necrosis factor (TNF)-α inhibitors for psoriatic arthritis and plaque psoriasis in 2002 and 2004, respectively, MTX remains the first-line systemic therapy for these disorders. Biologics are reserved for patients with psoriasis who are poorly controlled on MTX or when there are contraindications to its use. Heavy alcohol consumption (> 100 g/wk) while taking MTX increases the risk of MTX hepatotoxicity